Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical company creating recombinant protein nanoparticle vaccines to address a broad range of infectious diseases. The company is developing a portfolio of vaccine candidates targeting seasonal and pandemic influenza (H5N1), a vaccine designed to protect children and the elderly against respiratory syncytial virus (RSV), rabies and other candidates. In addition, the company is developing its vaccine candidates for worldwide commercialization including:
Our world-class scientific team is using VLP technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbreak. Our team has created vaccine candidates that are in various phases of clinical testing designed to protect against various circulating strains of pandemic influenza including H1N1 and H5N1, as well as seasonal influenza. Our recombinant nanoparticle protein micelle technology targeted at RSV has been tested in various preclinical studies and has now advanced into clinical testing.
Our vision is to control the spread of infectious diseases by using a unique single-use manufacturing system that allows for the rapid mass production of recombinant protein nanoparticle vaccines. Our goal is to be able to rapidly deliver a customized vaccine in the midst of a declared pandemic.
President and Chief Executive Officer
Stanley C. Erck
Senior Vice President, Research and Development
Gregory M. Glenn, M.D.
Senior Vice President, Manufacturing and Process Development
Timothy J. Hahn, Ph.D.
Senior Vice President, Chief Financial Officer and Treasurer
Barclay A. "Buck" Phillips
Senior Vice President, Business Development
Russell P. "Rip" Wilson
Vice President, Regulatory Affairs
Amy B. Fix
Vice President, Chief Medical Officer
Louis F. Fries III, M.D.
Vice President, Manufacturing
Mervyn L. Hamer
Vice President, General Counsel and Corporate Secretary
John A. Herrmann III, J.D.
Vice President, Process Development
Erica Shane, Ph.D.
Vice President, Vaccine Development
Gale Smith, Ph.D.
Vice President, Clinical Operations
D. Nigel Thomas, Ph.D.
Novavax’s clinical program includes vaccine candidates designed to address infectious diseases worldwide. Using innovative virus-like particle (VLP) and recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Our clinical pipeline is shown below.